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ABSTRACT

Elucidating mechanisms of hepatitis B virus (HBV)-mediated hepatocarcinogenesis is needed to gain
insights into the etiology and treatment of liver cancer. Cells where HBV is replicating exhibit increased expression of Plk1 kinase and reduced levels of two transcription repression factors, SUZ12 and ZNF198. SUZ12 is an essential subunit of the transcription repressive complex PRC2. ZNF198 stabilizes the transcription repressive complex composed of LSD1, Co-REST and HDAC1. These two transcription repressive complexes are held together by binding the long noncoding RNA HOTAIR. In this study we linked these regulatory events mechanistically, by showing that Plk1 induces proteasomal degradation of SUZ12 and ZNF198 by site-specific phosphorylation. Plk1-dependent ubiquitination of SUZ12 and ZNF198 was enhanced by expression of HOTAIR, significantly reducing SUZ12 and ZNF198 stability.
In cells expressing the HBV X protein (HBx) downregulation of SUZ12 and ZNF198 mediated global changes in histone modifications. In turn, HBx-expressing cells propagated an altered chromatin landscape after cell division, as exemplified by changes in histone modifications of the EpCAM promoter, a target of PRC2 and LSD1/Co-REST/HDAC1 complexes. Notably, liver tumors from X/cmyc bitransgenic mice exhibited downregulation of SUZ12 and ZNF198 along with elevated expression of Plk1, HOTAIR, and EpCAM. Clinically, similar effects were documented in a set of HBV-related liver tumors consistent with the likelihood that downregulation of SUZ12 and ZNF198 leads to epigenetic reprogramming of infected hepatocytes. Since both Plk1 and HOTAIR are elevated in many human cancers, we propose that their combined effects are involved in epigenetic reprogramming associated broadly with oncogenic transformation.
INTRODUCTION
Chronic infection by the Hepatitis B virus is a major etiologic factor in the development of hepatocellular carcinoma (HCC) (1) . The World Health Organization estimates that 250 million people globally are chronically infected with HBV. Despite the availability of the HBV vaccine, the vaccine is not always protective and children born of infected mothers become chronically infected. Current treatments include antiviral nucleoside analogs, but eventually this treatment results in viral resistance (2) . In advanced stage HCC, targeted therapies such as sorafenib (anti-MAPK) are of modest but significant benefit (3) . Thus, new and effective mechanism-based therapies are needed, along with new prognostic markers for molecular staging of the disease (4).
Pathogenesis of HBV-mediated HCC involves effects of chronic inflammation of the liver (5) and
effects of the HBV X protein (HBx), which acts as a weak oncogene (6) or co-factor in hepatocarcinogenesis (7) . HBV DNA integrates into the host genome at early steps of clonal tumor expansion and the majority of tumors display continued expression of HBx (8) . HBx is a multifunctional protein (9 , 10) , is required for the HBV life cycle (11) , and is implicated in HCC pathogenesis by a
mechanism not yet understood. Regarding this mechanism, our studies (12 , 13 ) discovered an inverse relationship between the protein levels of two transcription repressive factors, SUZ12 and ZNF198, and the mitotic polo-like-kinase1 (Plk1) (14) . This intriguing relationship between Plk1, SUZ12 and ZNF198 was observed in cellular and animal models of HBx-and HBV-mediated oncogenic transformation as well as in HBV replicating cells (15) . SUZ12 is one of the three essential subunits of the transcription repressive PRC2 complex (polycomb repressive complex 2). The other two core subunits of PRC2 include EED protein and the histone methyltransferase EZH2 (16) . This chromatin modifying complex epigenetically regulates lineage selection during embryonic development and stem cell differentiation (17, 18) by trimethylating histone3 on lysine 27 (H3K27me3), a transcription silencing modification (16) . PRC2 forms multi-protein complexes with other chromatin modifying proteins (19, 20) , and associates with noncoding RNAs (21) .
PRC2 binds the long noncoding RNA (lncRNA) HOTAIR which also binds another transcription repressive complex composed of lysine demethylase1 (LSD1), Co-REST, and histone deacetylase 1(HDAC1) (22). Interestingly, the LSD1/Co-REST/HDAC1 complex which enzymatically removes histone acetylations and H3K4 methylations that activate transcription, is stabilized by the chromosomal protein ZNF198 (23). Thus, HOTAIR couples the transcription repressive activity of PRC2 and LSD1/Co-REST/HDAC1 complexes (22). In addition to the involvement of these chromatin modifying complexes in cell fate determination during embryonic development, accumulating evidence links deregulated expression of polycomb proteins (24) and ZNF198 (25 , 26) to cancer pathogenesis.
In liver tumors of X/c-myc bitransgenic mice and those induced by chronic infection with Woodchuck hepatitis virus (WHV), increased protein levels of Plk1 correlated with reduced protein levels of SUZ12 and ZNF198 (15) . Our studies suggested that Plk1, activated by HBx in late G2 phase (27), is responsible for down-regulating the protein levels, but not the transcription of SUZ12 and ZNF198 (12, 13, 27) . Studies by others have shown that Plk1 phosphorylation induces proteasomal degradation of its substrates involved in cell cycle progression (28 , 29). Elevated Plk1 occurs in various types of human cancers, including liver cancer (30). The function of Plk1 substrates ranges from proteins involved in mitotic progression, chromosome segregation, DNA replication, and signal transduction (28-30). In this study we show that Plk1 signals by phosphorylation the proteasomal degradation of the chromatin modifying proteins SUZ12 and ZNF198. Clinically, elevated expression of HOTAIR and Plk1 was quantified in aggressive liver tumors derived from chronically infected HBV patients, supporting the involvement of this novel mechanism in HBV-mediated hepatocarcinogenesis.
MATERIALS AND METHODS
Cell culture, transfections, plasmids, siRNAs and synchronization protocols: Tetracycline regulated HBx-expressing 4pX-1 cells, derived from mouse hepatocyte AML12 cell line (31), was grown as described (32), in the presence of tetracycline (5µg/ml) or without tetracycline for 16-18h to allow HBx expression. HBx expression was confirmed by RT-PCR. Synchronization of 4pX-1 cells in G1/S by the double thymidine block (dTB) was performed as described (27) . Synchronization of 4pX-1 cells in G2/M was by incubation with 100 nM nocodazole for 12h, and release from the block for 4h. HepAD38 cells, In vitro Plk1 kinase assays: performed exactly as described (35 , 36) employing affinity purified SUZ12-HA and ZNF198-GFP following transient expression in HEK293 cells. Site-directed mutagenesis of putative Plk1 phosphorylation sites in SUZ12-HA and ZNF19-GFP was performed employing the QuickChange site-directed mutagenesis kit (Stratagene). Mutations were confirmed by DNA sequencing.
Immunoblots, immunoprecipitations and immunofluorescence microscopy were performed employing standard protocols (13) . 
RESULTS
HBx and Plk1 regulate protein levels of SUZ12 and ZNF198. To investigate whether Plk1, which becomes activated by HBx expression (27), downregulates SUZ12 and ZNF198 proteins (15), we transfected mammalian expression vectors encoding SUZ12-HA and ZNF198-GFP in tetracyclineregulated HBx-expressing 4pX-1 cells (32). Expression of HBx decreased by > 50% protein levels of transfected SUZ12-HA and ZNF198-GFP as well as endogenous SUZ12 and ZNF198 proteins (Fig. 1A ).
To link this HBx-mediated downregulation of SUZ12 and ZNF198 to Plk1, HEK293T cells transfected with SUZ12-HA and ZNF198-GFP were treated with Plk1 inhibitor BI2536 or proteasomal inhibitor MG132 (Fig. 1B) . Treatment with BI2536 or MG132 restored SUZ12-HA and ZNF198-GFP protein levels ( Fig. 1B) , suggesting SUZ12 and ZNF198 are down-regulated via Plk1 mediated phosphorylation.
These effects of HBx on SUZ12 and ZNF198 proteins were also observed in HBV replicating HepAD38 cells (13 , 15) . In the HepAD38 cellular model of HBV replication the integrated HBV genome is under control of the Tet-off promoter (33). HBV replication is initiated by tetracycline removal, allowing transcription of the pregenomic RNA, the template of viral replication. In the presence of HBV replication, using the viral core protein HBc as marker for HBV replication, endogenous SUZ12 and ZNF198 protein levels were reduced (Fig. 1C) . Importantly, employing the phospho-T210 Plk1 (Plk1T 210 ) antibody that detects active Plk1, we observe that in HBV replicating cells Plk1 was activated (Fig. 1C ) and localized to the nucleus (Fig. 1D ).
Plk1 phosphorylates SUZ12 and ZNF198 in vitro. Since SUZ12 and ZNF198 are nuclear proteins and active Plk1 was in the nucleus of HBV replicating cells (Fig. 1D) , these results suggest SUZ12 and ZNF198 could serve as Plk1 substrates. To test this hypothesis, we performed in vitro Plk1 assays (Fig.   2 ). SUZ12-HA and ZNF198-GFP proteins were expressed by transient transfection in HEK293T cells and purified by affinity chromatography. In vitro kinase assays with affinity purified substrates and Plk1 (36) were performed in the presence of γ-P 32 -ATP, analyzed by SDS PAGE, and autoradiography (35 , 36) . Indeed, wild-type (WT) SUZ12 and ZNF198 proteins were phosphorylated in vitro by Plk1 ( Fig.   2A ).
Next, we examined the protein sequence of SUZ12 and ZNF198 for conserved, consensus Plk1 phosphorylation sites (D/E-X-S/T-Φ-D/E), and constructed Ser to Ala substitutions at those sites ( Fig.   2B ). Phosphoproteomic studies have shown SUZ12 is phosphorylated in vivo at S546 using nocodazolearrested Hela cells (37) and S539 in human embryonic stem cells, hESCs (38) ; on the other hand, ZNF198 is phosphorylated in vivo at S305 using nocodazole-arrested Hela cells (39) . However, the kinase(s) mediating these phosphorylations are unknown.
To determine if these sites in SUZ12 and ZNF198 are phosphorylated by Plk1, we expressed each mutant protein in HEK293T cells, purified them by affinity chromatography, and performed in vitro Plk1 kinase assays ( Fig. 2C-D ). SUZ12 proteins with Ser to Ala substitutions at residues 539, 541 and 546 (single and triple site mutants) were used in in vitro kinase assays. The results show that all three sites were phosphorylated by Plk1, the triple mutant showing 70% reduction in phosphorylation (Fig. 2C) , and identify Plk1 as the kinase mediating the in vivo detected phosphorylations of SUZ12 at S539 and S546 (37 , 38 Similar analyses with ZNF198 identified two clusters of putative Plk1 phosphorylation sites in vitro.
A cluster of serine residues at the N-terminus of ZNF198, S303, S305, and S309, and a cluster at the Cterminus, S1056 and S1064. The triple Ser to Ala mutant, S303A/S305A/S309A, consistently exhibited the lowest level of phosphorylation in vitro, in comparison to the double S1056A/S1064A mutant (Fig.   2D ). Importantly, in vivo phosphorylation of S305 of ZNF198 was detected by phosphoproteomic studies (39) , suggesting that Plk1 is the kinase that phosphorylates S305 of ZNF198 in vivo.
Plk1 phosphorylation dissociates SUZ12-and ZNF198-containing complexes. In SUZ12, residues 539, 541 and 546 phosphorylated by Plk1 in vitro (Fig. 2C ), are adjacent (S539 and S541) and within (S546) the VEFS box ( (Fig. 3A) . To confirm these results we examined endogenous EZH2 interaction with SUZ12 mutants containing Ser to Ala or Ser to Asp substitutions at all three sites (S539, S541 and S546).
The phospho-mimetic substitutions (Ser to Asp) significantly reduced interaction of SUZ12 with EZH2 (Fig. 3B) .
We also examined whether Plk1-mediated phosphorylation of ZNF198 disrupts interaction with LSD1/Co-REST/HDAC1 complex (23). ZNF198-GFP was co-transfected with either Plk1 Similar results were observed with WT ZNF198-GFP (Fig. 4B) ; compare lane 6 without BI2536 vs. lane 3 with BI2536. Since ubiquitination of SUZ12 and ZNF198 depends on active Plk1 (Fig. 4A and B) , we examined the ubiquitination potential of their Plk1 phosphorylation mutants in transfected HEK293T cells. The triple Ser to Ala mutants of SUZ12 and ZNF198 (Fig. 2) lacked ubiquitination (Fig. S1A and   S1B ), supporting that Plk1-mediated phosphorylations at those sites are necessary for ubiquitination.
HOTAIR increases ubiquitination of SUZ12 and ZNF198, reducing their stability. HOTAIR functions as scaffold in ubiquitination by interacting with RNA binding E3 ubiquitin ligases (41) . Since HOTAIR bridges PRC2 to the LSD1/Co-REST/HDAC1 complex, stabilized by ZNF198 (23), we investigated whether HOTAIR has a role in ubiquitination of SUZ12 and ZNF198. We co-transfected in HEK293T Fig. S1C and D, and Fig. 4C and D) . By contrast, the triple mutants of SUZ12 and ZNF198 that cannot be phosphorylated by Plk1 (Fig. 2) lacked ubiquitination, even with HOTAIR overexpression (Fig. 4C and D ).
To directly demonstrate the role of Plk1 and HOTAIR on the stability of SUZ12 and ZNF198
proteins, we quantified their half-life (t1/2) following treatment with cyclohexamide (CHX) (Fig. 4E-F the triple SUZ12 and ZNF198 mutants that cannot be phosphorylated by Plk1 (Fig. 2) , exhibited enhanced stability, even in the presence of active Plk1 CA and HOTAIR. By contrast, the t1/2 of Cterminal ZNF198 mutant (S1056A/S1064A) resembled WT ZNF198 (Fig. 4F) . We interpret these results to mean that HOTAIR facilitates ubiquitination of Plk1-phosphorylated SUZ12 and ZNF198 proteins, thereby accelerating their proteasomal degradation.
To confirm that this mechanism is operational with endogenous SUZ12 and ZNF198 proteins, we coexpressed Plk1 CA and HOTAIR in HBV-replicating HepAD38 cells. Expression plasmids were tranfected on day-1 after tetracycline removal, and cells were harvested 48h later. Co-expression of Plk1 CA and HOTAIR significantly reduced endogenous levels of ZNF198 and SUZ12 (Fig. 4G) .
Interestingly, under these conditions HBc levels increased by 11-fold, in agreement with earlier results showing that knockdown of SUZ12 and ZNF198 enhances HBV replication (13). 
HBx downregulates SUZ12 and ZNF198 during cell cycle progression in untransformed hepatocytes and alters the chromatin landscape of daughter cells. To investigate whether this mechanism occurs in HBx-expressing cells, we employed tetracycline-regulated HBx-expressing 4pX-1 cells (32). HBx activates Plk1 in late G2 phase (27). Employing double thymidine block (dTB) to synchronize 4pX-1 cells in G1/S, with or without HBx expression (27), we monitored protein levels of SUZ12 and ZNF198 as a function of cell cycle progression. Samples were collected at 4h (S phase), 8h (G2) and 10h (late G2/M) after release from dTB, as a function of HBx expression and BI2536 treatment (Fig. S3A) .
Immunoblots demonstrate reduction in SUZ12 and ZNF198 levels with HBx expression (Fig. 5A , lanes
5-8) that parallels activation of Plk1 (p-Plk1
T210
) from 4h to 10h after release from dTB (Fig. 5A , lanes 5-8 and Table S1 ). Importantly, treatment of HBx-expressing cells with BI2536 reversed this reduction (Fig. 5A, lanes 9-12) . Next, we determined the effect of the reduction in SUZ12 and ZNF198 proteins on global H3 modifications mediated by the PRC2 and LSD1/Co-REST/HDAC1 complexes, respectively.
Concomitant with the reduction in SUZ12, we observed reduction in H3K27me3 levels in HBxexpressing cells. Conversely, the levels of activating modifications on H3K4 were increased. Treatment of HBx-expressing cells with BI2536 reversed these effects (Table S1 shows quantification of Fig. 5A ).
Since HBx, via Plk1-mediated down-regulation of SUZ12 and ZNF198, altered global histone modifications during cell cycle progression (Fig. 5A) , we investigated whether these epigenetic changes are propagated to daughter cells. We synchronized 4pX-1 cells in G2/M by nocodazole, released cells from the block for 4h, allowing progression to G1 phase (Fig. S3B) . Employing chromatin immunoprecipitation assays (ChIP), we examined H3 modifications of the EpCAM promoter, a target of the PRC2 and LSD1/Co-REST/HDAC1 complexes (15) . ChIP assays show that HBx expression decreased the silencing H3K27me3 modification mediated by PRC2, while the activating histone modification H3K4me1, associated with loss of LSD1 function, was increased (Fig. 5B) (Fig. 5C) . Moreover, the reduction in endogenous SUZ12 and ZNF198 levels was restored by treatment with Plk1 inhibitor BI2536 and siRNA knockdown of HOTAIR (Fig. 5C ), supporting involvement of both Plk1 and HOTAIR in their downregulation. Lastly, protein levels of endogenous SUZ12 and ZNF198 were stabilized in CHX-and BI2536-treated cells (Fig. 5D) , further supporting the role of Plk1 in SUZ12 and ZNF198 degradation.
Plk1 and HOTAIR are elevated in liver tumors of X/c-myc mice and chronic HBV-infected patients.
Liver tumors from X/c-myc bitransgenic mice (6) exhibit increased levels of Plk1 and reduced levels of SUZ12 and ZNF198 proteins (15) . Based on the mechanism of Plk1-mediated degradation of SUZ12 and ZNF198 described in this study (Fig. 4) , we quantified expression levels of Plk1 and HOTAIR RNAs in liver tumors from X/c-myc bitransgenic mice. We observed enhanced expression of Plk1 mRNA and HOTAIR in the same tumor, ranging from 2-fold to > than 10-fold (Fig. 6A, right panel) . We also quantified Plk1 and HOTAIR RNA levels in liver tumors of chronically infected HBV patients (Fig. 6B) .
Group B patients exhibits at least 2-fold increased expression of both Plk1 and HOTAIR.
Since, liver tumors of X/c-myc bitransgenic mice display increased expression of EpCAM (15, and Fig. 6C left panel) , we also quantified EpCAM expression in the HBV-related HCCs. Interestingly, increased EpCAM expression was observed in Group B HCCs, those displaying at least 2-fold increased expression of Plk1 and HOTAIR (Fig. 6C, right panel) . Lastly, we determined the clinical significance of the expression of Plk1 and HOTAIR in HBV-related HCCs (Table 1) 
DISCUSSION
Liver tumors from X/c-myc bitransgenic mice and woodchucks chronically infected by WHV display an inverse relationship between Plk1 and chromatin regulating proteins SUZ12 and ZNF198 (15) . In this study we provide evidence of a direct, causal link between Plk1 activation and reduced protein levels of SUZ12 and ZNF198. As shown in the model (Fig. 6D ), Plk1 phosphorylates SUZ12 and ZNF198 at specific sites (Fig. 2) , disrupts their association with the respective chromatin modifying complexes ( Fig.   3 ) and signals proteasomal degradation of SUZ12 and ZNF198 by ubiquitination (Fig. 4) . Interestingly, their ubiquitination is facilitated by HOTAIR, acting as ubiquitination scaffold (41) . The combined action of active Plk1 and HOTAIR accelerates degradation of SUZ12 and ZNF198, decreasing their halflife by >15-fold, while the mutants of SUZ12 and ZNF198 that cannot be phosphorylated by Plk1 are stable (Fig. 4) . The E3 ubiquitin ligases involved in this mechanism are presently unknown, although the RNA binding E3 ligases Dzip3 and Mex3b, shown to bind to HOTAIR (41) , are likely candidates.
This novel mechanism that regulates SUZ12 and ZNF198 stability is significant for several reasons. enzymatic activity (44) (45) (46) and substrate specificity (47). Recent studies have identified a series of molecular steps initiated by oncogenic Ras signaling that epigenetically silence tumor suppressor genes (48). However, in addition to silencing tumor suppressor genes, oncogenic signaling must epigenetically modify chromatin components to activate transcription of genes linked to proliferation and oncogenic transformation. In this study we identified such a mechanism, involving Plk1, overexpressed in many human cancers (28), regulating the stability of epigenetic regulators.
2. This mechanism is operational upon activation of Plk1 by HBx, shown in the model of Fig. 6D , occurring during cell cycle progression, in the G2 phase ( 3. The involvement of HOTAIR in significantly decreasing the stability of SUZ12 and ZNF198 in the presence of activated Plk1 is another important discovery of this study (Fig. 4) . The elevated expression of Plk1 and HOTAIR in liver tumors of X/c-myc bitransgenic mice as well as in a group of human HBVrelated HCCs (Fig. 6 ) supports the relevance of this mechanism to HBV-mediated liver carcinogenesis. 
leading to re-expression of genes silenced by these complexes. Indeed, we detect enhanced expression of EpCAM both in liver tumors of X/c-myc mice as well as in Group B HCCs of HBV-infected patients (Fig. 6C) , those dispaying elevated expression of both Plk1 and HOTAIR. The strong correlation between enhanced HOTAIR expression and the aggressive HCC phenotype supports the significance of this mechanism to HCC pathogenesis (Table 1) , and the potential use of HOTAIR expression as a biomarker for aggressive HCC. Since Plk1 and HOTAIR are overexpressed in many human cancers (50), including a group of HBV-mediated HCCs (Fig. 6) , we speculate this novel mechanism contributes to cellular reprograming observed during oncogenic transformation. 
